If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
This was discovered in the earliest nuclear reactors built by the American Manhattan Project for plutonium production. Because of this effect, designers must make provisions to increase the reactor's reactivity (the number of neutrons per fission that go on to fission other atoms of nuclear fuel) over the initial value needed to start the chain reaction. For the same reason, the xenon fission products produced in a nuclear explosion and a power plant differ significantly as a large share of 135Xe will absorb neutrons in a steady state reactor, while in a bomb it can be assumed that none of the 135I will have had time to decay to xenon before the explosion disperses it, removing it from the neutron radiation. Relatively high concentrations of radioactive xenon isotopes are also found emanating from nuclear reactors due to the release of this fission gas from cracked fuel rods or fissioning of uranium in cooling water. The concentrations of these isotopes are still usually low compared to the naturally occurring radioactive noble gas 222Rn. Because xenon is a tracer for two parent isotopes, Xe isotope ratios in meteorites are a powerful tool for studying the formation of the Solar System. The I-Xe method of dating gives the time elapsed between nucleosynthesis and the condensation of a solid object from the solar nebula (xenon being a gas, only that part of it that formed after condensation will be present inside the object). Xenon isotopes are also a powerful tool for understanding terrestrial differentiation.
Dulaglutide, sold under the brand name Trulicity, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. This medication is often prescribed for adults and children age 10 and older with type 2 diabetes (citation). It is utilized alongside diet and exercise in order to improve blood sugar. It is also approved in the United States for the reduction of major adverse cardiovascular events such as death, heart attack, or stroke in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is not yet known if it is beneficial, safe, or effective in lowering blood sugar in children under 10 years of age. Trulicity is taken by giving an injection once a week under the skin of your stomach, thigh, or upper arm. The medication is a prescription that comes in the form of a pre-filled single-dose pen in 0.75mg, 1.5mg, 3mg, or 4.5mg per 5mg injection. You are able to take the dosage at any time during the day of administration with/without food eaten. The most common side effects upon administration are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. Dulaglutide injection is in a class of medications called incretin mimetics, as it is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. GLP-1 is a hormone that is involved in normalizing the level of glucose in blood (glycemia). It works by aiding the pancreas to release the correct amount of insulin when blood sugar levels are high.
==== Effects in animals and humans ==== According to Alexander Shulgin in PiHKAL, phenethylamine is completely inactive in humans at doses of up to 1,600 mg orally and 50 mg intravenously. This can be attributed to its extremely rapid metabolic breakdown rather than pharmacodynamic inactivity. Although exogenous phenethylamine on its own is inactive, its metabolism can be strongly inhibited and it can thereby become active, showing psychostimulant effects, when combined with a monoamine oxidase inhibitor (MAOI), specifically monoamine oxidase B (MAO-B) inhibitors like selegiline. Oral L-phenylalanine (a precursor of phenethylamine) and/or phenethylamine itself in combination with selegiline has been studied in the treatment of depression and has been reported to be effective. Misuse of phenethylamine in combination with selegiline has also been reported. The LD50Tooltip median lethal dose values of phenethylamine include 175 mg/kg i.p. in mice, 320 mg/kg s.c. in mice, 100 mg/kg i.v. in mice, 100 mg/kg parenterally in mice, 39 mg/kg intracervically in mice, and 200 mg/kg i.p. in guinea pigs. Its LDLo values include 800 mg/kg p.o. in rats, 100 mg/kg i.p. in rats, 450 μg/kg s.c. in rats, and 300 mg/kg via an unspecified route in mice.
Encouraged by South Africa's apparent failure to detect the initial incursion, larger insurgent groups made their own infiltration attempts in February and March 1966. The second unit, "Group 2", was led by Leonard Philemon Shuuya, also known by the nom de guerre "Castro" or "Leonard Nangolo". Group 2 apparently become lost in Angola before it was able to cross the border, and the guerrillas dispersed after an incident in which they killed two shopkeepers and a vagrant. Three were arrested by the Portuguese colonial authorities in Angola, who were working off tips received from local civilians. Another eight, including Shuuya, had been captured between March and May by the South African police, apparently in Kavangoland. Shuuya later resurfaced at Kongwa, claiming to have escaped his captors after his arrest. He helped plan two further incursions: a third SWALA group entered Ovamboland that July, while a fourth was scheduled to follow in September.
Sources: en.wikipedia.org
== Analytical methods == Given the large diversity of PFAS structures that exist, analytical methods for PFAS analysis generally take one of two different approaches: targeted analysis or non-targeted analysis. Targeted methods narrow focus on known PFAS of concern (e.g. PFOA, PFOS) and generally use solid-phase extraction with liquid chromatography–mass spectrometry (LC-MS) detection. For example, EPA Method 537.1 is approved for use in drinking water and can quantify 18 PFAS compounds, while EPA Method 1633A is approved for use for wastewater, surface water, groundwater, soil, biosolids, sediment, landfill leachate, and fish tissue for 40 PFAS chemicals. Regulatory limits for PFOA and PFOS set by the US EPA (4 parts-per-trillion) are limited by the capability of targeted methods to detect low-level concentrations. Non-targeted analyses often sacrifice the identification and quantification of specific PFAS compounds to better understand the amount of PFAS present as a class. For example, total organic fluorine (TOF) analysis quantifies the amount of fluoride produced when a sample is oxidized at high enough temperatures to break the carbon-fluorine bond using combustion ion chromatography. Variants of this analysis include adsorbable organic fluorine (AOF) and extractable organic fluorine (EOF), which use similar solid-phase extraction approaches as the targeted analysis, but use combustion ion chromatography (CIC) as a detector.
The head of the Ukrainian Defense Industry claimed that Ukraine's production of suicide drones identical to Shahed 131s and Shahed 136s had caught up with Russia's production of Shahed drones. He also claimed that Ukrainian manufacturing reached parity with Russia's production of other strike drones, and that Ukrainian forces have already used domestically produced drones similar to Russia's Lancet drones.
An advocacy group that has taken a position against research on newborn blood screening data without parental consent is the Citizens' Council for Health Freedom, who take the position that newborn health screening for "a specific set of newborn genetic conditions" is a very different matter than storing the data or those DNA samples indefinitely to "use them for genetic research without parental knowledge or consent."
In one interpretation of the film's plot, a scientific process supposedly extracts hydrogen from water, then burns the hydrogen to generate power, and leaves only water as a residue, essentially a chemical perpetual motion. The movie never clarifies how the hydrogen is extracted from the water, nor how water is still left over. The character Dr. Shannon makes contradictory statements in the combination of ideas mashed together: one time he says this is accomplished with a laser with millions of degrees, another time he says frequencies of sound and sonoluminescence. In one scene, the movie shows a bubbling container reminiscent of cold fusion electrolytic cells and another reference sustained fusion. A character in the film claims that a glass of water could power Chicago for weeks, but no clear explanation is ever given as to whether this is by simply burning hydrogen released by highly efficient means or through nuclear processes. The film's title is also misleading, since "chain reaction" is related to nuclear fission, not fusion. The film is based on the premise that free energy suppression is real. The main character is told that his discovery is too disruptive: energy would suddenly be cheap, oil would no longer be necessary, oil companies would go bankrupt, and such sudden economic changes would throw society into chaos.
=== Phototherapy === Phototherapy is considered a second-line treatment for vitiligo. Due to the higher risks of skin cancer with ultraviolet A (UVA) light, the United Kingdom's National Health Service suggests that it be used only if primary treatments are ineffective. The risk of skin cancer with UVB is unclear and commercially available lamps are not regulated, but 311 nm is considered the most effective wavelength, with the combined intake of antioxidant supplements believed to suppress oxidative stress. UVA treatments are normally carried out in a hospital clinic. Psoralen and ultraviolet A light (PUVA) treatment involves taking a drug that increases the skin's sensitivity to ultraviolet light and then exposing the skin to high doses of UVA light. Treatment is required twice a week for 6–12 months or longer. Due to the high doses of UVA and psoralen, PUVA may cause side effects such as sunburn-type reactions or skin freckling. Broadband ultraviolet B therapy is given three times a week. Narrowband ultraviolet B (NBUVB) phototherapy lacks the side effects caused by psoralens and is as effective as PUVA. Treatment is carried out 2–3 times weekly in a clinic. Longer treatment is often recommended over at least 6 months. The most effective responses are on the face and neck. Topical calcineurin inhibitors plus phototherapy produces better results than phototherapy alone, hydrocortisone plus laser light is better than laser light alone, ginkgo biloba is better than placebo, and oral mini-pulse of prednisolone (OMP) plus NB-UVB is better than OMP alone.
Sources: en.wikipedia.org
== Sources == Furlow, John J. (1997). "Betula". In Flora of North America Editorial Committee (ed.). Flora of North America North of Mexico (FNA). Vol. 3. New York and Oxford: Oxford University Press – via eFloras.org, Missouri Botanical Garden, St. Louis, Missouri and Harvard University Herbaria, Cambridge, Massachusetts. Li, Pei-chun; Skvortsov, Alexei K. "Betula". Flora of China. Vol. 4 – via eFloras.org, Missouri Botanical Garden, St. Louis, Missouri and Harvard University Herbaria, Cambridge, Massachusetts. Grimshaw, John (2009). New Trees, Recent introductions to cultivation. Kew Publishing, RBG Kew. pp. 163–174. Chisholm, Hugh, ed. (1911). "Birch" . Encyclopædia Britannica. Vol. 3 (11th ed.). Cambridge University Press. Jonczak, Jerzy; Jankiewicz, Urszula; Kondras, Marek; Kruczkowska, Bogusława; Oktaba, Lidia; Oktaba, Jarosław; Olejniczak, Izabella; Pawłowicz, Edyta; Polláková, Nora; Raab, Thomas; Regulska, Edyta; Słowińska, Sandra; Sut-Lohmann, Magdalena (December 2020). "The influence of birch trees (Betula spp.) on soil environment – A review". Forest Ecology and Management. 477 118486. Bibcode:2020ForEM.47718486J. doi:10.1016/j.foreco.2020.118486.
There are some common misconceptions about the outer and inner chloroplast membranes. The fact that chloroplasts are surrounded by a double membrane is often cited as evidence that they are the descendants of endosymbiotic cyanobacteria. This is often interpreted as meaning the outer chloroplast membrane is the product of the host's cell membrane infolding to form a vesicle to surround the ancestral cyanobacterium—which is not true—both chloroplast membranes are homologous to the cyanobacterium's original double membranes. The chloroplast double membrane is also often compared to the mitochondrial double membrane. This is not a valid comparison—the inner mitochondria membrane is used to run proton pumps and carry out oxidative phosphorylation across to generate ATP energy. The only chloroplast structure that can be considered analogous to it is the internal thylakoid system. Even so, in terms of "in-out", the direction of chloroplast H+ ion flow is in the opposite direction compared to oxidative phosphorylation in mitochondria. In addition, in terms of function, the inner chloroplast membrane, which regulates metabolite passage and synthesizes some materials, has no counterpart in the mitochondrion.
=== Humans === The cycling of and excretion of urea by the kidneys is a vital part of mammalian metabolism. Besides its role as carrier of waste nitrogen, urea also plays a role in the countercurrent exchange system of the nephrons, that allows for reabsorption of water and critical ions from the excreted urine. Urea is reabsorbed in the inner medullary collecting ducts of the nephrons, thus raising the osmolarity in the medullary interstitium surrounding the thin descending limb of the loop of Henle, which makes the water reabsorb. By action of the urea transporter 2, some of this reabsorbed urea eventually flows back into the thin descending limb of the tubule, through the collecting ducts, and into the excreted urine. The body uses this mechanism, which is controlled by the antidiuretic hormone, to create hyperosmotic urine — i.e., urine with a higher concentration of dissolved substances than the blood plasma. This mechanism is important to prevent the loss of water, maintain blood pressure, and maintain a suitable concentration of sodium ions in the blood plasma. The equivalent nitrogen content (in grams) of urea (in mmol) can be estimated by the conversion factor 0.028 g/mmol. Furthermore, 1 gram of nitrogen is roughly equivalent to 6.25 grams of protein, and 1 gram of protein is roughly equivalent to 5 grams of muscle tissue. In situations such as muscle wasting, 1 mmol of excessive urea in the urine (as measured by urine volume in litres multiplied by urea concentration in mmol/L) roughly corresponds to a muscle loss of 0.67 grams.
The lethal dose of psilocybin when administered intravenously in mice is 285 mg/kg, in rats is 280 mg/kg, and in rabbits is 12.5 mg/kg. Psilocybin comprises approximately 1% of the weight of Psilocybe cubensis mushrooms, and so nearly 1.7 kilograms (3.7 lb) of dried mushrooms, or 17 kilograms (37 lb) of fresh mushrooms, would be required for a 60-kilogram (130 lb) person to reach the 280 mg/kg LD50 value of rats. Based on the results of animal studies and limited human case reports, the human lethal dose of psilocybin has been extrapolated to be 2,000 to 6,000 mg, which is around 1,000 times greater than its effective dose of 6 mg and 200 times the typical recreational dose of 10 to 30 mg. The Registry of Toxic Effects of Chemical Substances assigns psilocybin a relatively high therapeutic index of 641 (higher values correspond to a better safety profile); for comparison, the therapeutic indices of aspirin and nicotine are 199 and 21, respectively. The lethal dose from psilocybin toxicity alone is unknown, and has rarely been documented—as of 2011, only two cases attributed to overdosing on hallucinogenic mushrooms (without concurrent use of other drugs) have been reported in the scientific literature, and those may involve factors other than psilocybin.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.